NCT02858245

Brief Summary

A prospective, open-label, and multi-centered feasibility registry.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2016

Geographic Reach
1 country

8 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 20, 2016

Completed
19 days until next milestone

First Posted

Study publicly available on registry

August 8, 2016

Completed
3 months until next milestone

Study Start

First participant enrolled

November 1, 2016

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

May 7, 2018

Status Verified

May 1, 2017

Enrollment Period

1.1 years

First QC Date

July 20, 2016

Last Update Submit

May 2, 2018

Conditions

Keywords

MitraClipStructural Heart FailureDegenerative Mitral Regurgitation (DMR)Actigraphy

Outcome Measures

Primary Outcomes (1)

  • Observational change in daily reported activity levels (counts/min) as assessed by actigraphy, from baseline to 30 days post MitraClip implantation

    Phillips Actiwatch Spectrum PRO is the device being used to capture the primary outcome measure

    At 30 days

Secondary Outcomes (20)

  • Levels of daily and weekly activity as assessed by actigraphy

    Pre-procedure (on day 0)

  • Levels of daily and weekly activity as assessed by actigraphy

    Post-procedure (≤ 7 days)

  • Levels of daily and weekly activity as assessed by actigraphy

    At 30 days

  • Levels of daily and weekly activity as assessed by actigraphy

    At 2 months

  • Levels of daily and weekly activity as assessed by actigraphy

    At 3 months

  • +15 more secondary outcomes

Study Arms (1)

Commercial MitraClip® patients

Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device

Other: No intervention - registry

Interventions

Commercial MitraClip® patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Prohibitive risk degenerative mitral regurgitation (DMR) patients who receive at least 1 commercial MitraClip

You may qualify if:

  • Subject must consent to receiving the MitraClip device
  • Subject must consent, be able, and commit to wearing the Actiwatch continuously for approximately 7 months
  • Subject must consent to use of their data from this registry for purposes of exploratory research and publication and presentation

You may not qualify if:

  • Subject is not a member of vulnerable population
  • Subject must not have any disabilities that preclude reliable data collection from the Actiwatch, e.g., epilepsy with uncontrolled recurring episodes, serious stage degenerative/disabling disease (e.g. Parkinson's disease), inability to walk or will require walking aids, etc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Banner University Medical Center

Phoenix, Arizona, 85006, United States

Location

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States

Location

University of Colorado Hospital

Aurora, Colorado, 80045, United States

Location

Baptist Hospital of Miami

Miami, Florida, 33176, United States

Location

Mayo Foundation for Medical Education and Research

Rochester, Minnesota, 55905, United States

Location

Carolinas Medical Center

Charlotte, North Carolina, 28203, United States

Location

The Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

Bon Secours St Mary's Hospital

Richmond, Virginia, 23226, United States

Location

MeSH Terms

Conditions

Mitral Valve Insufficiency

Condition Hierarchy (Ancestors)

Heart Valve DiseasesHeart DiseasesCardiovascular Diseases

Study Officials

  • Peter Staehr, MD

    Abbott Medical Devices

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 20, 2016

First Posted

August 8, 2016

Study Start

November 1, 2016

Primary Completion

December 1, 2017

Study Completion

December 1, 2017

Last Updated

May 7, 2018

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will not share

Locations